SLB anticipates decrease in global upstream investment in 2025
North America is particularly vulnerable to these anticipated short-cycle expenditure cuts, whereas regions such as Asia and the Middle East appear more robust thanks to lower production costs, national energy security imperatives and investments in gas projects.
The decline in crude prices by more than 21% in the April–June quarter compared to the previous year has heightened concerns over a wider-scale pullback in exploration and production investments, reported Reuters.
SLB has highlighted the ongoing market uncertainty influenced by factors such as OPEC+ supply decisions, trade talks and geopolitical tensions.
SLB CEO Olivier Le Peuch said: "The market is navigating several dynamics – including fully supplied oil markets, OPEC+ supply releases, ongoing trade negotiations and geopolitical conflicts.
'Despite this, commodity prices have remained range bound. Meanwhile, customers have selectively adjusted activity, prioritising key projects and planning cautiously, particularly in offshore deep-water markets.'
The company also noted that the tariffs imposed by US President Donald Trump could impact its margins by 20–40 basis points in the latter half of the year.
Despite these challenges, SLB reported total revenue of $8.55bn in the second quarter (Q2), surpassing the anticipated $8.48bn.
SLB experienced a surge due to increased offshore activities and heightened drilling demand in the United Arab Emirates, Kuwait and Iraq.
North American revenues saw a 1% increase to $1.66bn compared to last year, bolstered by advancements in data-centre infrastructure solutions.
The company's earnings, excluding specific charges and credits, amounted to $0.74 per share for the quarter ending 30 June, marginally exceeding the average forecast of $0.73.
Meanwhile, SLB also recently finalised the acquisition of ChampionX, a deal first announced in April of the previous year.
The completion followed the receipt on Tuesday of the last required regulatory consent from UK authorities.
"SLB anticipates decrease in global upstream investment in 2025" was originally created and published by Offshore Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Why QuantumScape Stock Is Sinking Today
Key Points QuantumScape is sinking after Goldman Sachs published bearish coverage on the stock. Goldman raised its one-year price target on QuantumScape from $2 per share to $3 per share, but it maintained a sell rating on the stock. QuantumScape's solid-state batteries could be revolutionary, but the stock is a high-risk play. 10 stocks we like better than QuantumScape › QuantumScape (NYSE: QS) stock is being hit with big sell-offs Friday in response to bearish analyst coverage. The company's share price was down 6.3% as of 3 p.m. ET. despite the S&P 500 being up 0.4% and the Nasdaq Composite being up 0.3% at the same point in the day. The stock had been down as much as 11.9% earlier in trading. Shortly before the market closed yesterday, Goldman Sachs published new coverage on QuantumScape and reiterated a sell rating on the stock. Despite some recent pullbacks, the company's share price is still up 127% this year. QuantumScape stock sinks following bearish coverage With its coverage yesterday, Goldman Sachs raised its one-year price target on QuantumScape from $2 per share to $3 per share but kept a sell rating on the stock. Mark Delaney, the firm's lead analyst on the solid-state battery specialist, said he saw some encouraging signs with QuantumScape's new Cobra manufacturing process and the expansion of its deal with Volkswagen's PowerCo subsidiary, but he remained heavily bearish on the stock due to a belief that big risk factors facing the business aren't reflected in its current valuation. As of this writing, the investment firm's price target implies potential downside of roughly 74.5% for the stock. What's next for QuantumScape? QuantumScape's solid-state battery technologies have the potential to make big waves in the electric vehicle (EV) industry by offering superior charge capacity, faster charging, and safety improvements. On the other hand, it still remains to be seen whether they will actually wind up being brought to market and used by Volkswagen's PowerCo and other potential customers. With its recent quarterly report, the company announced that it had secured a new deal with PowerCo worth $131 million and that it now had enough cash to fund its operations through 2029. QuantumScape stock could deliver huge returns if its solid-state batteries see market adoption, but the stock is a speculative play and could see big sell-offs if the company hits roadblocks on the path to commercialization. Do the experts think QuantumScape is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did QuantumScape make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,040% vs. just 182% for the S&P — that is beating the market by 858.13%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Volkswagen Ag. The Motley Fool has a disclosure policy. Why QuantumScape Stock Is Sinking Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 928,596 shares of common stock of the Company originally issued in December 2024 and January 2025, having exercise prices between $2.00 and $3.00 per share. Warrants to purchase 100,000 shares of common stock at the existing exercise price of $2.00 per share will be exercised at their existing exercise price of $2.00 per share and warrants to purchase 828,596 shares of common stock will be exercised at a reduced exercise price of $2.485 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statement on Form S-1 (No. 333-284381). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.5 million, prior to deducting placement agent fees and offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional $232,149 in the aggregate, which are included in the gross proceeds to the Company), the exercising holders will receive new unregistered warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"). The new warrants will be exercisable for an aggregate of up to 1,857,192 shares of common stock, at an exercise price of $2.485 per share and will be immediately exercisable upon issuance and (i) will have a term of twenty-four months with respect to new warrants to purchase up to 1,538,596 shares of common stock and (ii) will have a term of five years with respect to new warrants to purchase up to 318,596 shares of common stock, in each case, following the effective date of the resale registration statement registering the shares of common stock issuable upon exercise of the new warrants. The offering is expected to close on or about July 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes. The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the 1933 Act and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. For additional information, visit the Company's website, Forward-Looking Statements completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law. Contact:Phio Pharmaceuticals Phillips: jphillips@ Affairs To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Lira Hits Rock Bottom After Shock Rate Cut -- Is the Carry Trade Party Over?
Morgan Stanley (NYSE:MS) is urging caution on the Turkish liraeven as it still delivers positive returns in real terms. The call follows a 300 basis-point rate cut by Turkey's central bank on Thursday, which dragged the lira to a record low of 41.9184 per dollar. That brings year-to-date losses to about 13%, but thanks to high inflation, carry traders have continued to pocket real gains. Still, Morgan Stanley flagged a faster pace of depreciation and crowded positioning that could start to unwind. Warning! GuruFocus has detected 6 Warning Signs with MCO. Goldman Sachs previously called the lira one of the most profitable carry trades globallybut warned that its shine could fade if policymakers let the currency slide further. Thursday's cut, which pushed the policy rate down to 43%, may have caught some off guard, but Deutsche Bank framed it as a front-loaded adjustment rather than a pivot away from prudence. Barclays added that as long as dollar-adjusted returns hover around 1% per month, the trade remains palatable. But that confidence could be fragile if volatility creeps back in. Now the market's attention shifts to sovereign rating updates due Friday from Moody's (NYSE:MCO) and Fitch. Moody's has Turkey rated four notches below investment grade (with a positive outlook), while Fitch is three notches below (stable). Whether recent disinflation trends and macro stabilization efforts are enough to move the needle remains to be seen. Political risk, including the recent arrest of Istanbul Mayor Ekrem Imamoglu, is still lurking in the backdropand could be what tips the scale, not economic data alone. This article first appeared on GuruFocus. Sign in to access your portfolio
